Voyager Pharmaceutical, a developer of drugs for diseases associated with aging and development, announced Friday evening that it plans to offer 5.9 million shares at a range of $15-$19. The company has an Alzheimer's drug, Memryte, in Phase III clinical trials. WR Hambrecht will underwrite the deal using its Dutch auction-style IPO process. Timing has yet to be determined.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
